New 1277 m³ facility to bring 150 extra controlled drug storage pallets, 450 extra refrigerated cold storage pallets with room for further expansion.
Almac Clinical Service today announced the opening of an additional storage facility at its EU headquarters in Craigavon to meet the increased demands for cold-chain & controlled clinical supply storage.
The huge new facility has been fuelled by unprecedented demand in the marketplace for provision of supply services catering for biotech and pharma companies requiring refrigerated or controlled storage requirements for their clinical supplies.
This new purpose built facility contains a 1277m³ vault, holding an additional 150 pallet spaces for controlled drug storage. The facility provides 450 extra pallet spaces for storage of refrigerated material (2-8°C), with room for an additional future expansion of 400 pallets. This extra capacity is in addition to that already available at the site.
This latest development is in line with Almac's continued expansion plans, as already reflected in the significant expansions for cold storage at the groups Durham (NC) and Audubon (PA) sites. This new state-of-the-art facility combined with Almac’s global depot network ensures Almac continues as a world leader in the provision of clinical supply services and solutions.
Robert Dunlop, President of Almac Clinical Services said: ‘The opening of the new storage warehouse is a testimony to our commitment to providing the highest quality of service and available capacity to our customers. As demand for both controlled drug and cold chain storage has grown steadily in recent times, we must provide our offerings in line with market demands. This positions Almac firmly as a market leader for clinical supplies, offering unrivalled cold chain & controlled drug resources for our client base.’
About Almac Clinical Services
Almac Clinical Services is a global company focused on clinical trial supply solutions, with sites in Craigavon (UK), Audubon (PA, USA) and Durham (NC, USA). Almac Clinical Services enables clients to meet their trial start dates by leveraging skilled and experienced personnel coupled with robust quality systems and operational flexibility. Services provided include blinding, packaging, labelling, global distribution, QP release, analytical testing, drug supply management and online randomization.
About Almac
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, product development, clinical trial supply and technology (IVRS/EDC), to commercial-scale manufacture. Almac provides services to over 600 companies including all the world leaders in the pharmaceutical and biotech sectors.
The company has almost 2,200 employees and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Construction of the company's new $100m North American Headquarters started in July 08 and is expected to be completed 2010.
To find out more about Almac visit
www.almacgroup.com
.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.